Table 3.
Clinical follow-up and treatment
| Patient | Time from RE to symptoms (wk) | Clinical follow-up time (mo) |
Symptoms (CTCAE v4.02 grading scale) |
Treatment |
Weight loss1 (kg) | Hemoglobin2 (g/dL) | Reason for end of endoscopic follow up | ||||
| Pain | Nausea and vomiting | Anorexia | Treatment used | Time on treatment (mo) | Clinical response | ||||||
| 1 | 4 | 6 | Epigastric pain (1) | No | No | Pantoprazole, domperidone and almagate | 4 | Yes | 6 | -1.5 | Improvement |
| 2 | 4 | 29 | Epigastric pain (1) | Yes (1) | No | Esomeprazole, cinitapride sucralfate and ranitidine | 8 | Yes | 7 | -0.6 | Improvement |
| 3 | 4 | 88 | Epigastric pain (2) | Yes (1) | Yes (3) | Pantoprazole, metoclopramide, sucralfate and cinitapride | 10 | Yes | 17 | -6.9 | Improvement |
| 4 | 2 | 9 | Left subcostal pain (2) | Yes (1) | No | Pantoprazole, sucralfate and almagate | 5 | Yes | 4 | -3.1 | Improvement |
| 5 | 12 | 88 | Epigastric pain (1) | Yes (1) | Yes (2) | Pantoprazole, pentoxifylline, esomeprazole and almagate | 5 | Yes | 4 | -1.6 | Improvement; still on follow-up |
| 6 | 4 | 3 | Epigastric pain (2) | Yes (2) | Yes (2) | Esomeprazole, pentoxifylline and misoprostole | 1 | No | 4.1 | -2.4 | Exitus |
1
Maximal loss of weight over 4 mo;
2
Maximal change in hemoglobin over 4 mo. CTCAE: Common Terminology Criteria for Adverse Events; RE: Radioembolization.